Today Stories

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio, including tirzepatide, with activin receptor blockers such as bimagrumab, could be the next major step in innovative treatments for those living with cardiometabolic diseases, like obesity," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "The wealth of knowledge that our new colleagues from Versanis will bring to L…

The two organizations are joining forces to develop pioneering AI-based solutions for efficient chemical synthesis planning to accelerate the development of novel pharmaceuticals. COLUMBUS, Ohio & WARSAW, Poland--(BUSINESS WIRE)--CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules. Leveraging their existing technologies and expertise, including Molecule.one’s proprietary generative deep learning models and…

Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the receptor protein CB1 – which plays an important role in metabolism and appetite regulation – in peripheral tissues such as adipose tissues, the gastro-intestinal tract, the kidneys…

INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new colleagues from DICE, we look forward to continuing our pursuit of discovering and delivering life…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s opti-oxTM precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies. / bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration. Cambridge, MA USA 7:30 am and Cambridge, UK 12:30pm, August 3, 2023: BlueRock Therapeutics LP, a clinical stage cell t…

Envisioning the future of regulatory and medical writing, CAPTIS Copilot leverages cutting-edge AI models for the Medical Device and Diagnostic industry. CHICAGO--(BUSINESS WIRE)--Celegence, a regulatory compliance service and software solution company, today announced the launch of CAPTIS Copilot, the most advanced document automation and literature review solution for the life sciences industry. CAPTIS Copilot is an enterprise cloud-based platform leveraging pre-trained large language models (LLM) and Reinforcement Learning from Human Feedback (RLHF) for the device and diagnostic industry. This cloud-based solution significantly advances the ability of device and IVD manufacturers to increase innovation and empower clinical, regulatory, and medical writing teams to be more strategic and…

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebone Laboratory (Marylebone Lab Ltd) has introduced ColoAlert®, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal ca…

– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations in Africa, South America, Asia and Oceania, Europe and North America  –  Themed ‘Test. Link. Prioritize’, the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 –  SINGAPORE, July 28, 2023 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of ‘Test. Link. Prioritize’, designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications…

Agreement furthers Alexion’s ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca’s commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies. As part of the agreement, the transaction will bring to Alexion a number of novel adeno-associated virus…

Bracknell, UK, 27th July 2023 – PharmiWeb.Jobs, the world’s premier life science job board, is excited to announce that the platform has now reached over 500,000 registered jobseekers, globally. This remarkable milestone signifies the team’s commitment to connecting life science professionals with the best career opportunities in the industry, whilst helping recruiters and hiring managers locate the top talent they need to drive their organisations forward. “Reaching half a million registered jobseekers is a real testament to the dedication of our team who work so hard to keep us at the forefront of what we do,” said Vincent Lody, Managing Director of PharmiWeb. “We have seen incredible growth over the past few years and look forward to continuing this growth on a truly global scale.” For…

DEERFIELD, Ill. - 2023-07-25 Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions.  “Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as chief executive officer of the new company upon spinoff. “The Vantive name reflects our dedicated employees’ steadfast commitment to patients a…

Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeutics Zilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressure Hypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1 Basel, 24 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic currently in Phase 2 for the trea…

– $6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities. Gilead is in discussions with two Indigenous-led organizations, the Lowitja Institute in Australia and CAAN Communities, Alliances & Networks in Canada, to create the new $6 million USD grant program, with funding divided equally between the two countries and invested over three years. The gra…

– Funding Will Support the Re-Engagement of Diagnosed but Untreated People Living with HCV and HBV in the United States into Care – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overseeing Gilead Relink, including distributing funds to grantees identified by CDAF that meet certain criteria, integral strategic planning and technical assistance. …

Alpha-1 antitrypsin (AAT) is an immuno-modulator with broadband anti-inflammatory and antiviral therapeutic effects AATec Medical is developing recombinant AAT initially for respiratory applications in combination with novel inhalation technology Clinical studies are expected to start in first half of 2024 Financing is supported by private investors, industry experts and family offices Company is led by experienced team of sector specialists Munich, Germany – 17 July 2023 – AATec Medical GmbH (AATec), a German biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced that it has commenced operations with seed financing of EUR 2.7 million from private investors, industry experts and family offices. The funds will be used to scale u…

Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their risk of disease progression; nearly half of participants at earlier stage of disease on donanemab had no clinical progression at 1 year Additional subpopulation analyses presented live showed that those study participants at earliest stage of disease had even greater benefit, with 60% slowing of decline compared to placebo Furthermore, treatment effect continued to increase relative to placebo over the course of the trial, even though many participants completed their course of therapy at 6 or 12 months, supporting limited duration dosing FDA submission completed in Q2; regulatory action expected by end of year INDIANAPOLIS, July 17, 2023 /PR…

INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese. Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-…

Supporting You with UC Provides Patients with Resources to Help Manage Their UC and Tips on Ways to Communicate with Their Doctor PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) has launched Supporting You with UC, an ulcerative colitis (UC) educational campaign with patient ambassador* Rosie White. The Supporting You with UC website includes White’s personal UC diagnosis and treatment journey, along with a collection of practical resources for people living with the disease to help manage symptoms on the go and in their everyday lives. There are approximately 600,000 to 900,000 people in the United States living with UC — a chronic, immune-mediated inflammatory bowel disease (IBD).1,2,3 UC presents as a range of symptoms that can be unique to each patient, hard to pr…

Agreement Will Expand Access to Labcorp's Diagnostics Capabilities and Improve Services BURLINGTON, N.C., July 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has entered into an agreement with Legacy Health to acquire select assets of its outreach laboratory business, including laboratory facilities and equipment. Labcorp will also manage Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply chain services and laboratory support. Legacy will maintain ownership and licensure of its hospital laboratories as well as retain ownership of its central lab building at Holladay Park in Northeast Portland.  Legacy is a si…